Late-breaking ADA analysis examines a urinary modified Fetuin-A biomarker for earlier renal risk stratification in type 2 diabetes with chronic kidney disease.
Key Takeaways
- CREDENCE established SGLT2 inhibitors as foundational therapy for diabetic kidney disease
- Analysis evaluated baseline DNlite in 2,429 CREDENCE participants across placebo and canagliflozin arms
- DNlite assay independently predicted adverse renal outcomes beyond albuminuria and eGFR